These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 4641856)

  • 21. Synergistic cooperation between isoantiserum and immune lymphoid cells: in vitro studies with a syngeneic rat lymphoma.
    Ortiz de Landazuri M; Kedar E; Fahey JL
    J Immunol; 1974 Jun; 112(6):2102-10. PubMed ID: 4825787
    [No Abstract]   [Full Text] [Related]  

  • 22. Antibody-dependent peritoneal-cell-mediated cytotoxicity in man.
    Podleski WK; Podleski UG
    Lancet; 1973 Jun; 1(7816):1389. PubMed ID: 4122776
    [No Abstract]   [Full Text] [Related]  

  • 23. Requirement for a radiosensitive lymphoid cell in the generation of lipopolysaccharide-induced rejection of a murine tumor allograft.
    Berendt MJ; Mezrow GF; Saluk PH
    Infect Immun; 1978 Sep; 21(3):1033-5. PubMed ID: 711328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogeneity of the effector cells in the cytotoxic reaction against allogeneic lymphoma cells.
    Forman J; Britton S
    J Exp Med; 1973 Feb; 137(2):369-86. PubMed ID: 4539847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alteration of skin in gross leukemia. V. Refutation of virus involvement.
    Mariani T; Maruyama Y
    J Natl Cancer Inst; 1974 Dec; 53(6):1661-4. PubMed ID: 4612164
    [No Abstract]   [Full Text] [Related]  

  • 26. Characteristics of xenograft. II. Cytostatic effector mechanism for xenograft rejection.
    Nomoto K; Terasaka R; Himeno K; Shiraishi M
    Jpn J Exp Med; 1981 Apr; 51(2):81-7. PubMed ID: 6974263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Facilitation of macrophage-mediated destruction of allogeneic fibrosarcoma cells by tumor-enhancing IgG 2 in vitro.
    Cruse JM; Whitten HD; Lewis GK; Watson ES
    Transplant Proc; 1973 Mar; 5(1):961-7. PubMed ID: 4695960
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effect of peritoneal macrophages on cellular and humoral cytotoxicity in rats with experimental Shvetz leukemia].
    Serafimov-Dimitrov V; Nedialkova MP; Decheva-Ninova Z
    Probl Gematol Pereliv Krovi; 1976 Oct; 21(10):43-6. PubMed ID: 1005377
    [No Abstract]   [Full Text] [Related]  

  • 29. Suppressed development of cytotoxic lymphoid cells in tumor-immunized mice.
    Martin WJ; Wunderlich JR; Macdonald J
    Isr J Med Sci; 1973 Mar; 9(3):324-31. PubMed ID: 4710040
    [No Abstract]   [Full Text] [Related]  

  • 30. Evidence for the suppression of the development of cytotoxic lymphoid cells in tumor immunized mice.
    Martin WJ; Esber E; Wunderlich JR
    Fed Proc; 1973 Feb; 32(2):173-9. PubMed ID: 4688656
    [No Abstract]   [Full Text] [Related]  

  • 31. The PLL gene and histocompatibility genotype in inbred and random-bred guinea pigs.
    Ellman L; Green I; Benacerraf B
    J Immunol; 1971 Aug; 107(2):382-8. PubMed ID: 5568769
    [No Abstract]   [Full Text] [Related]  

  • 32. Distribution and lysis of weakly and strongly immunogenic malignant lymphoid cells in normal and immune mice: effects of prior exposure to heat or X-irradiation.
    Nawrocki JF; Look AT; Selwa JF; Haggis JR; Murphy WH
    J Natl Cancer Inst; 1984 May; 72(5):1085-94. PubMed ID: 6585585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electronic cell volume analysis of growth and rejection of EL-4 ascites tumor cells.
    Zucker RM; Harari J; Finley J; Kambour M
    Am J Vet Res; 1978 Oct; 39(10):1710-2. PubMed ID: 717886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro induction of tumor-specific immunity. I. Parameters of activation and cytotoxic reactivity of mouse lymphoid cells immunized in vitro against syngeneic and allogeneic plasma cell tumors.
    Wagner H; Röllinghoff M
    J Exp Med; 1973 Jul; 138(1):1-15. PubMed ID: 4541509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune response to an allogeneic progressively growing solid tumor.
    Eggers AE
    Cancer Res; 1976 Jun; 36(6):2085-9. PubMed ID: 773534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-reactivity of incompatible lymphoid cells from f1 modified radiation chimeras to host tumour cells in vitro.
    Grant CK; Ilbery PL
    Biomedicine; 1973 Feb; 19(2):56-60. PubMed ID: 4581503
    [No Abstract]   [Full Text] [Related]  

  • 37. Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570).
    Liepins A; Nowicky JW
    Drugs Exp Clin Res; 1996; 22(3-5):103-13. PubMed ID: 8899312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional capacity of cytotoxic lymphoid cells.
    Wunderlich JR; Martin WJ; Macdonald J; Fletcher F
    Natl Cancer Inst Monogr; 1972 Dec; 35():243-9. PubMed ID: 4676543
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunization of rats against the Yoshida ascites hepatoma with viable cells injected subcutaneously or intramuscularly.
    Bellelli L; Nista A; Sezzi ML
    Oncology; 1971; 25(3):249-57. PubMed ID: 4340708
    [No Abstract]   [Full Text] [Related]  

  • 40. Definition of a unique cell surface antigen of mouse leukemia RL male 1 by cell-mediated cytotoxicity.
    Nakayama E; Shiku H; Takahashi T; Oettgen HF; Old LJ
    Proc Natl Acad Sci U S A; 1979 Jul; 76(7):3486-90. PubMed ID: 91166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.